{"id":"NCT00976716","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain","officialTitle":"An Open-Label, Multicenter Study To Evaluate The Efficacy, Safety And Tolerability Of Celecoxib (YM177) In Patients With Posttraumatic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2009-09-14","resultsPosted":"2011-05-19","lastUpdate":"2021-02-02"},"enrollment":80,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"Celecoxib","otherNames":[]}],"arms":[{"label":"Celecoxib","type":"EXPERIMENTAL"}],"summary":"To investigate efficacy, safety and tolerability of Celecoxib in patients with posttraumatic pain for the duration of 8 days.","primaryOutcome":{"measure":"Patient Impressions at Final Visit (the Number of Participants Who Have Rated \"Excellent\" and \"Good\")","timeFrame":"8 days","effectByArm":[{"arm":"Celecoxib","deltaMin":70,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191357&StudyName=An%20Open-Label%20Study%20Of%20Celecoxib%20In%20Patients%20With%20Posttraumatic%20Pain"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":["Beta 2 microglobulin urine increased","Beta-N-acetyl-D-glucosaminidase increased","Blood creatine phosphokinase increased","Blood lactate dehydrogenase increased","Diarrhoea"]}}